Skip to main content
. 2021 May 27;11:676135. doi: 10.3389/fonc.2021.676135

Figure 1.

Figure 1

IP-10 is associated with metastatic progression. (A) Secreted protein levels of MIG, IP-10 and I-TAC in an ex vivo liver MPS for the hepatic niche alone, with growing breast cancer cells, with dormancy breast cancer cells or with emergent breast cancer cells determined using Luminex technology (median with quartiles and range; Mann-Whitney test; n = 4-6 donors). Ex vivo data sourced from: Clark et al. (19). (B) RNA expression levels human patients with in stage IV metastatic breast cancer (log10 transformation, median with quartiles and range, Wilcoxon matched-pairs signed rank test, *** p < 0.001). (C) Survival of the aforementioned patients based on high and low expression of IP-10, I-TAC, MIG and CXCR3 (Kaplan-Meyer survival analyzed with Gehan-Breslow-Wilcoxon test). (B,C) Human TCGA breast cancer data sourced from: Human Protein Atlas version 19.3 (http://www.proteinatlas.org; n = 19 patients). (D) mRNA expression levels of IP-10 in patients with TNBC compared to all other subtypes of breast cancer (median with quartiles and range; Mann-Whitney test, ****p < 0.0001). The human breast cancer dataset (31, 32) containing the hormone status data was sourced from cBioPortal v3.6.11 (33, 34) (n = 1903 patients).